Literature DB >> 35512874

Impact of the COVID-19 Pandemic on Respiratory Infection Rates.

Susan M Cullinan1, Heather A Heaton2, Aidan Mullan2, John O'Horo2, Matthew J Binnicker2, Aaron J Tande2, Jason A Post2, Ronna L Campbell2, Neha P Raukar2.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35512874      PMCID: PMC8942707          DOI: 10.1016/j.mayocp.2022.03.012

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


× No keyword cloud information.
To the Editor: A substantial change in the pattern of influenza infections was noted worldwide during the COVID-19 pandemic. We sought to describe our experience with seasonal respiratory infections across 60 sites of a major health care system in the Midwest United States. Although timing varies slightly from year to year, seasonal acute respiratory infections, such as influenza A/B, respiratory syncytial virus (RSV), and group A streptococcus (GAS), have predictable months of increased activity. We collected the number of tests performed for influenza A/B, RSV, GAS, and SARS-CoV-2 from November 1, 2018, to March 31, 2020 (ie, the pre-pandemic period) and April 1, 2020, to June 24, 2021 (ie, the pandemic period). During the COVID-19 pandemic, we observed lower rates of influenza A/B than previously reported and discovered substantially decreased positivity rates for RSV and GAS as well.1, 2, 3, 4 A total of 1,489,293 tests were performed for influenza A/B, RSV, GAS, and SARS-CoV-2 between November 1, 2018, and June 24, 2021 (Table ; Supplemental Figure, available online at http://www.mayoclinicproceedings.org). Our pre-pandemic interval includes 2 typical respiratory seasons with peaks from November through March, during which time 11% of all influenza tests returned positive results, 8% of RSV test results were positive, and 25% of GAS test results were positive. In comparison, during the COVID-19 pandemic, there were only 28 (0.02%) positive influenza results of 139,816 tests, 24 (0.2%) positive RSV results of 11,412 tests, and 5622 (13.2%) positive cases of GAS of 42,485 tests. Even though the overall rate of testing of influenza A/B and RSV was lower during the pandemic, the positivity rate decreased significantly (P<.001), more than would be predicted, and approached zero.
Table

Tests for Acute Respiratory Infections Performed and Results

Pre-pandemic perioda (n=350,334)Pandemic periodb,c (n=1,138,959)Overall (N=1,489,293)
Test performed
 Influenza A/B20,8438 (59.5)139,816 (12.3)348,254 (23.4)
 Respiratory syncytial virus37,717 (10.8)11,436 (1.0)49,153 (3.3)
 Group A streptococcus93,392 (26.7)42,485 (3.7)135,877 (9.1)
 SARS-CoV-210,787 (3.1)945,222 (83.0)956,009 (64.2)
Influenza A/B test results
 Negative185,311 (88.9)139,788 (100.0)325,099 (93.4)
 Positive23,127 (11.1)28 (0.0)23,155 (6.6)
Respiratory syncytial virus test results
 Negative34,711 (92.0)11,412 (99.8)46,123 (93.8)
 Positive3006 (8.0)24 (0.2)3030 (6.2)
Group A streptococcus test results
 Negative70,306 (75.3)36,863 (86.8)107,169 (78.9)
 Positive23,086 (24.7)5622 (13.2)28,708 (21.1)
SARS-CoV-2 test results
 Negative10,739 (99.6)865,086 (91.5)875,825 (91.6)
 Positive48 (0.4)80,136 (8.5)80,184 (8.4)

Values are reported as number (percentage).

Pre-pandemic period: November 1, 2018, to March 31, 2020.

Pandemic period: April 1, 2020, to June 24, 2021.

All P values are <.001.

Tests for Acute Respiratory Infections Performed and Results Values are reported as number (percentage). Pre-pandemic period: November 1, 2018, to March 31, 2020. Pandemic period: April 1, 2020, to June 24, 2021. All P values are <.001. Patients tested for non-COVID viruses during the pandemic tended to be older (median age, 41.7 years; Q1-Q3, 19.9-66.5 years) compared with patients tested during the pre-pandemic period (median age, 28.7 years; Q1-Q3, 7.9-59.4 years; Wilcoxon, P<.001). However, there was no age difference in comparing positive non-COVID test results between the pandemic (median age, 14.6 years; Q1-Q3, 8.3-25.9 years) and the pre-pandemic periods (median age, 12.8 years; Q1-Q3, 6.2-35.5 years, Wilcoxon, P=.466). We also investigated the possibility of viral interference by SARS-CoV-2 on the rate of respiratory viral infections. To assess this, we compared positivity rates of influenza A/B and RSV between patients who had previously tested positive for SARS-CoV-2 and patients who had not tested positive. Only respiratory tests conducted during the pandemic period were included in this subanalysis. To serve as a baseline, we also compared positivity rates among all patients during the pre-pandemic period with patients in the pandemic period who had no previous positive SARS-CoV-2 test results. We found that viral interference did not contribute in decreasing the rates of influenza or RSV. In conclusion, there was a significant decrease observed in the rate of positivity of 3 respiratory illnesses before and during the COVID-19 pandemic. The explanation for the decreased rates of influenza A/B, RSV, and GAS is likely to be multifactorial, and further work will be needed to determine all the elements influencing this change as we navigate future respiratory seasons.
  4 in total

1.  Impact of Public Health Interventions on Seasonal Influenza Activity During the COVID-19 Outbreak in Korea.

Authors:  Hyunju Lee; Heeyoung Lee; Kyoung-Ho Song; Eu Suk Kim; Jeong Su Park; Jongtak Jung; Soyeon Ahn; Eun Kyeong Jeong; Hyekyung Park; Hong Bin Kim
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

2.  Monitoring respiratory infections in covid-19 epidemics.

Authors:  Ka Hung Chan; Pak-Wing Lee; Crystal Ying Chan; Kin Bong Hubert Lam; Pak-Leung Ho
Journal:  BMJ       Date:  2020-05-04

3.  Trends in Viral Respiratory Infections During COVID-19 Pandemic, South Korea.

Authors:  Sujin Yum; Kwan Hong; Sangho Sohn; Jeehyun Kim; Byung Chul Chun
Journal:  Emerg Infect Dis       Date:  2021       Impact factor: 6.883

4.  Decreased Influenza Incidence under COVID-19 Control Measures, Singapore.

Authors:  Roy Jiunn Jye Soo; Calvin J Chiew; Stefan Ma; Rachael Pung; Vernon Lee
Journal:  Emerg Infect Dis       Date:  2020-04-27       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.